These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38340759)

  • 1. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.
    Lindsay JO; Hind D; Swaby L; Berntsson H; Bradburn M; Bannur C U; Byrne J; Clarke C; Desoysa L; Dickins B; Din S; Emsley R; Foulds GA; Gribben J; Hawkey C; Irving PM; Kazmi M; Lee E; Loban A; Lobo A; Mahida Y; Moran GW; Papaioannou D; Parkes M; Peniket A; Pockley AG; Satsangi J; Subramanian S; Travis S; Turton E; Uttenthal B; Rutella S; Snowden JA
    Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):333-345. PubMed ID: 38340759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
    Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
    Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial.
    Lindsay JO; Allez M; Clark M; Labopin M; Ricart E; Rogler G; Rovira M; Satsangi J; Farge D; Hawkey CJ; ; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):399-406. PubMed ID: 28497755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.
    Snowden JA; Hawkey C; Hind D; Swaby L; Mellor K; Emsley R; Mandefield L; Lee E; Badoglio M; Polge E; Labopin M; Gribben J; Pockley AG; Foulds GA; Lobo A; Travis S; Parkes M; Satsangi J; Papaioannou D; Lindsay JO; ;
    BMC Gastroenterol; 2019 May; 19(1):82. PubMed ID: 31151436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
    Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
    Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.
    Newsome PN; Fox R; King AL; Barton D; Than NN; Moore J; Corbett C; Townsend S; Thomas J; Guo K; Hull D; Beard HA; Thompson J; Atkinson A; Bienek C; McGowan N; Guha N; Campbell J; Hollyman D; Stocken D; Yap C; Forbes SJ
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):25-36. PubMed ID: 29127060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Efficacy of Autologous Haematopoietic Stem Cell Transplantation in Refractory Crohn's Disease Patients.
    Giordano A; Rovira M; Veny M; Barastegui R; Marín P; Martínez C; Fernández-Avilés F; Suárez-Lledó M; Domènech A; Serrahima A; Lozano M; Cid J; Ordás I; Fernández-Clotet A; Caballol B; Gallego M; Vara A; Masamunt MC; Giner À; Teubel I; Esteller M; Corraliza AM; Panés J; Salas A; Ricart E
    J Crohns Colitis; 2024 Oct; 18(10):1701-1712. PubMed ID: 38757210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease.
    Hommes DW; Duijvestein M; Zelinkova Z; Stokkers PC; Ley MH; Stoker J; Voermans C; van Oers MH; Kersten MJ
    J Crohns Colitis; 2011 Dec; 5(6):543-9. PubMed ID: 22115372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
    Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
    Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation.
    Hasselblatt P; Drognitz K; Potthoff K; Bertz H; Kruis W; Schmidt C; Stallmach A; Schmitt-Graeff A; Finke J; Kreisel W
    Aliment Pharmacol Ther; 2012 Oct; 36(8):725-35. PubMed ID: 22937722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell transplantation for induction of remission in medically refractory Crohn's disease.
    El-Nakeep S; Shawky A; Abbas SF; Abdel Latif O
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013070. PubMed ID: 35556242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
    Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
    Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.